White Paper: Can longitudinal electronic health record data identify patients at higher risk of developing long COVID?

Can longitudinal electronic health record data identify patients at higher risk of developing long COVID?

3	Priya Shanm	ugam ¹ , Molly Bair ¹ , Emma Pendl-Robinson ¹ , Xindi C. Hu ^{1,*} , on behalf of N3C consortiur	n
4	¹ Mathematic	a, Inc., Princeton, NJ 08543	
5	*Correspond	ing author:	
6	Xindi C. Hu,	ScD	
7	Mathematica	, Inc., Princeton, NJ 08543	
8	chu@mather	natica-mpr.com	
9			
10	Table of	contents	
11	Ab	stract	1
12	1.	Introduction	2
13	2.	Our approach to predicting long COVID	5
14	3.	Characteristics of Sample	6
15 16	4.	Summary statistics for Cognitive, Fatigue, and Respiratory variations of Long COVID	9
17	5.	Predictive model for long COVID outcomes	10
18	6.	Apply the fair machine learning framework to the long COVID predictive models	s. 12
19	Co	nclusion	13
20	Ac	knowledgements	15
21	Re	ferences	19
22	Tables		23
23	Та	ble 1: Analytic Sample	23
24	Та	ble 2: Model Performance Results	25
25	Та	ble 3: Coefficient Values for the Binary Logistic Regression Models	26
26	Та	ble 4: Impurity-Based Variable Importance Scores for the Random Forest Models	3.27
27			
28	Abstract		

- 29 With hundreds of millions of COVID-19 infections to date, a considerable portion of the population has
- 30 developed or will develop long COVID. Understanding the prevalence, risk factors, and healthcare costs

White Paper: Can longitudinal electronic health record data identify patients at higher risk of developing long COVID?

31	of long COVID can be of significant societal importance. To investigate the utility of large-scale
32	electronic health record (EHR) data in identifying and predicting long COVID, we analyzed a sample of
33	1.23 million participants from the National COVID Cohort Collaborative (N3C), a longitudinal EHR data
34	repository from 80 sites in the US with over 8 million COVID-19 patients. We characterized the
35	prevalence of long COVID using a few different types of definitions to illustrate their relative strengths
36	and weaknesses. Then we developed machine learning models to predict the risk of developing long
37	COVID using demographic factors and comorbidity in the EHR. The risk factors for long COVID include
38	patient age; sex; smoking status; and comorbidities characterized by the Charlson Comorbidity Index
39	(CCI). We were able to predict three types of long COVID with low to moderate levels of accuracy (AUC
40	0.599 - 0.734). We found that age and CCI were most predictive of long COVID diagnosis. Ongoing
41	work includes applying the fair machine learning framework to the long COVID predictive models. We
42	are implementing fairness and bias mitigation methods to model fitting through the following steps,
43	selecting fairness metrics, preparing data and model, evaluating fairness metrics, applying bias mitigation
44	methods to the dataset, and comparing model results and fairness metrics before and after the mitigation.
45	The objective is to achieve equalized odds, a statistical notion that ensures classification algorithms do not
46	discriminate against protected groups (such as sex and race/ethnicity). Results from the fairness-based
47	machine learning will be included in the conference presentation.

48

49 1. Introduction

50 By November 2022, 94% of the US population was estimated to have been infected by SARS-CoV-2 at 51 least once (Klaassen et al., 2022). This proportion continues to rise as COVID-19 remains as an important 52 public health threat. Some people recover quickly after the initial infection, while others (between 10% to 53 30%) continue to experience symptoms even months after the initial infection (Herman et al., 2022). Long 54 COVID is defined by the World Health Organization (WHO) as persistent symptoms and/or long-term 55 complications following a probable or confirmed SARS-CoV-2 infection, usually 3 months from acute

White Paper: Can longitudinal electronic health record data identify patients at higher risk of developing long COVID?

56	infection and lasting longer than 2 months with no probable alternative diagnosis (Nittas et al., 2022;
57	World Health Organization, 2021). However, many challenges exist around diagnosing and managing
58	patients with long COVID and identifying individuals who may have elevated risks of developing long
59	COVID. Partially because the long-term effects of COVID-19 may exhibit differently for different
60	people, or because tracking symptoms that can wax and wane over a long period of time can be difficult.
61	Here we leverage a longitudinal electronic health record (EHR) data repository to test a few definitions of
62	long COVID and develop a risk prediction model to identify patients at higher risks of developing long
63	COVID. With hundreds of millions of COVID-19 infections to date, a considerable portion of the
64	population has developed or will develop long COVID. Understanding the prevalence, risk factors, and
65	healthcare costs of long COVID can be of significant societal importance. The healthcare sector needs to
66	better understand the demand for medical care due to long COVID and be prepared to deliver that. Public
67	health sector needs to be able to identify population segments at elevated risks for long COVID in order
68	to design and implement targeted intervention strategies.
68 69	to design and implement targeted intervention strategies. More than 80 symptoms have been identified in the literature to be potentially associated with long
68 69 70	to design and implement targeted intervention strategies. More than 80 symptoms have been identified in the literature to be potentially associated with long COVID (Nasserie et al., 2021). Like the initial SARS-CoV-2 infection, long COVID could affect multiple
68 69 70 71	to design and implement targeted intervention strategies. More than 80 symptoms have been identified in the literature to be potentially associated with long COVID (Nasserie et al., 2021). Like the initial SARS-CoV-2 infection, long COVID could affect multiple organs and body systems. The most common symptoms include fatigue, dyspnea, cardiac abnormalities,
68 69 70 71 72	to design and implement targeted intervention strategies. More than 80 symptoms have been identified in the literature to be potentially associated with long COVID (Nasserie et al., 2021). Like the initial SARS-CoV-2 infection, long COVID could affect multiple organs and body systems. The most common symptoms include fatigue, dyspnea, cardiac abnormalities, cognitive impairment, sleep disturbances, symptoms of post-traumatic stress disorder, muscle pain,
 68 69 70 71 72 73 	to design and implement targeted intervention strategies. More than 80 symptoms have been identified in the literature to be potentially associated with long COVID (Nasserie et al., 2021). Like the initial SARS-CoV-2 infection, long COVID could affect multiple organs and body systems. The most common symptoms include fatigue, dyspnea, cardiac abnormalities, cognitive impairment, sleep disturbances, symptoms of post-traumatic stress disorder, muscle pain, concentration problems, and headache (Crook et al., 2021). In addition to a long list of symptoms,
 68 69 70 71 72 73 74 	to design and implement targeted intervention strategies. More than 80 symptoms have been identified in the literature to be potentially associated with long COVID (Nasserie et al., 2021). Like the initial SARS-CoV-2 infection, long COVID could affect multiple organs and body systems. The most common symptoms include fatigue, dyspnea, cardiac abnormalities, cognitive impairment, sleep disturbances, symptoms of post-traumatic stress disorder, muscle pain, concentration problems, and headache (Crook et al., 2021). In addition to a long list of symptoms, information on symptom severity, duration, and co-occurrence is generally lacking in the literature.
 68 69 70 71 72 73 74 75 	to design and implement targeted intervention strategies. More than 80 symptoms have been identified in the literature to be potentially associated with long COVID (Nasserie et al., 2021). Like the initial SARS-CoV-2 infection, long COVID could affect multiple organs and body systems. The most common symptoms include fatigue, dyspnea, cardiac abnormalities, cognitive impairment, sleep disturbances, symptoms of post-traumatic stress disorder, muscle pain, concentration problems, and headache (Crook et al., 2021). In addition to a long list of symptoms, information on symptom severity, duration, and co-occurrence is generally lacking in the literature. Several approaches exist among published studies to characterize long COVID: some uses a very liberal
 68 69 70 71 72 73 74 75 76 	to design and implement targeted intervention strategies. More than 80 symptoms have been identified in the literature to be potentially associated with long COVID (Nasserie et al., 2021). Like the initial SARS-CoV-2 infection, long COVID could affect multiple organs and body systems. The most common symptoms include fatigue, dyspnea, cardiac abnormalities, cognitive impairment, sleep disturbances, symptoms of post-traumatic stress disorder, muscle pain, concentration problems, and headache (Crook et al., 2021). In addition to a long list of symptoms, information on symptom severity, duration, and co-occurrence is generally lacking in the literature. Several approaches exist among published studies to characterize long COVID: some uses a very liberal definition of having at least one symptom which result in high percentage of patients estimated to have
 68 69 70 71 72 73 74 75 76 77 	to design and implement targeted intervention strategies. More than 80 symptoms have been identified in the literature to be potentially associated with long COVID (Nasserie et al., 2021). Like the initial SARS-CoV-2 infection, long COVID could affect multiple organs and body systems. The most common symptoms include fatigue, dyspnea, cardiac abnormalities, cognitive impairment, sleep disturbances, symptoms of post-traumatic stress disorder, muscle pain, concentration problems, and headache (Crook et al., 2021). In addition to a long list of symptoms, information on symptom severity, duration, and co-occurrence is generally lacking in the literature. Several approaches exist among published studies to characterize long COVID: some uses a very liberal definition of having at least one symptom which result in high percentage of patients estimated to have long COVID but is likely an overestimate (CDC, 2023), some focuses on the most salient symptoms like
 68 69 70 71 72 73 74 75 76 77 78 	to design and implement targeted intervention strategies. More than 80 symptoms have been identified in the literature to be potentially associated with long COVID (Nasserie et al., 2021). Like the initial SARS-CoV-2 infection, long COVID could affect multiple organs and body systems. The most common symptoms include fatigue, dyspnea, cardiac abnormalities, cognitive impairment, sleep disturbances, symptoms of post-traumatic stress disorder, muscle pain, concentration problems, and headache (Crook et al., 2021). In addition to a long list of symptoms, information on symptom severity, duration, and co-occurrence is generally lacking in the literature. Several approaches exist among published studies to characterize long COVID: some uses a very liberal definition of having at least one symptom which result in high percentage of patients estimated to have long COVID but is likely an overestimate (CDC, 2023), some focuses on the most salient symptoms like fatigue, headache, dyspnea and anosmia (Sudre et al., 2021), some focuses on symptom clusters to

White Paper: Can longitudinal electronic health record data identify patients at higher risk of developing long COVID?

80	A wide range of prevalence estimates for long COVID may be a result of non-standardized definition,
81	virulence of different SARS-CoV-2 variants, and population immunity. Prevalence of as high as 80% was
82	observed in early studies, using a lenient definition of at least one symptom, among patients who were
83	previously hospitalized (Nasserie et al., 2021). The Centers of Disease Control and Prevention (CDC)
84	estimated that nearly one in five American adults who have had COVID-19 still have long COVID (CDC,
85	2022). More recently, the Global Burden of Disease Long COVID Collaborators estimated that 6.2%
86	individuals have at least one of the three select-reported long COVID symptom clusters (Global Burden
87	of Disease Long COVID Collaborators, 2022). As a result of the uncertainty around the prevalence of
88	long COVID, the economic cost of long COVID is hard to fully grasp, but safe to assume it would be an
89	enormous number. Cutler and Summers estimated the economic costs of long COVID to be \$2.6 trillion
90	in 2020, and later updated it to be \$3.7 trillion as a result of higher prevalence of long COVID than
91	previously assumed (D. Cutler, 2022; D. M. Cutler & Summers, 2020).
92	The enormity of the economic costs and societal impact of long COVID highlights the necessity to
93	develop better methods for detecting, treating, and preventing long COVID. In this study, we analyzed
94	data from the National COVID Cohort Calleborative (N2C) a longitudinal FUD data repository from 90
95	data from the National COVID Conort Collaborative (NSC), a longitudinal EHR data repository from 80
	sites in the US with over 8 million COVID-19 patients (Haendel et al., 2021). We characterize the
96	sites in the US with over 8 million COVID-19 patients (Haendel et al., 2021). We characterize the prevalence of long COVID using a few different types of definitions to illustrate their relative strengths
96 97	sites in the US with over 8 million COVID-19 patients (Haendel et al., 2021). We characterize the prevalence of long COVID using a few different types of definitions to illustrate their relative strengths and weaknesses. Then we develop machine learning models to predict the risk of developing long COVID
96 97 98	data from the National COVID Conort Conaborative (NSC), a longitudinal EHR data repository from 80 sites in the US with over 8 million COVID-19 patients (Haendel et al., 2021). We characterize the prevalence of long COVID using a few different types of definitions to illustrate their relative strengths and weaknesses. Then we develop machine learning models to predict the risk of developing long COVID using demographic factors and comorbidity in the EHR. We discuss model performance with a focus on
96 97 98 99	data from the National COVID Conort Conaborative (N3C), a longitudinal EHR data repository from 80 sites in the US with over 8 million COVID-19 patients (Haendel et al., 2021). We characterize the prevalence of long COVID using a few different types of definitions to illustrate their relative strengths and weaknesses. Then we develop machine learning models to predict the risk of developing long COVID using demographic factors and comorbidity in the EHR. We discuss model performance with a focus on features with strong predictive power that can be utilized to design early detection or targeted intervention
96 97 98 99 100	data from the National COVID Conort Collaborative (N3C), a longitudinal EFR data repository from 80 sites in the US with over 8 million COVID-19 patients (Haendel et al., 2021). We characterize the prevalence of long COVID using a few different types of definitions to illustrate their relative strengths and weaknesses. Then we develop machine learning models to predict the risk of developing long COVID using demographic factors and comorbidity in the EHR. We discuss model performance with a focus on features with strong predictive power that can be utilized to design early detection or targeted intervention strategies. We the discuss how EHR data derived risk prediction model can be used to enhance an
96 97 98 99 100 101	data from the National COVID Conort Conaborative (NSC), a longitudinal EFR data repository from so sites in the US with over 8 million COVID-19 patients (Haendel et al., 2021). We characterize the prevalence of long COVID using a few different types of definitions to illustrate their relative strengths and weaknesses. Then we develop machine learning models to predict the risk of developing long COVID using demographic factors and comorbidity in the EHR. We discuss model performance with a focus on features with strong predictive power that can be utilized to design early detection or targeted intervention strategies. We the discuss how EHR data derived risk prediction model can be used to enhance an individual COVID-19 risk calculator, 19andMe, to support individual and clinical decision-making.
96 97 98 99 100 101 102	data from the National COVID Conort Conaborative (NSC), a longitudinal EHR data repository from so sites in the US with over 8 million COVID-19 patients (Haendel et al., 2021). We characterize the prevalence of long COVID using a few different types of definitions to illustrate their relative strengths and weaknesses. Then we develop machine learning models to predict the risk of developing long COVID using demographic factors and comorbidity in the EHR. We discuss model performance with a focus on features with strong predictive power that can be utilized to design early detection or targeted intervention strategies. We the discuss how EHR data derived risk prediction model can be used to enhance an individual COVID-19 risk calculator, 19andMe, to support individual and clinical decision-making. Ongoing work also includes assessing algorithmic bias and mitigating them using techniques including

White Paper: Can longitudinal electronic health record data identify patients at higher risk of developing long COVID?

104 2. Our approach to predicting long COVID

105 Several features of long COVID make identifying positive cases using claims and EHR data challenging. 106 First, some symptoms of long COVID may or may not be detectable, depending on which diagnostic test 107 is used (Mancini et al., 2021). Second, due to early skepticism within the medical profession about the 108 existence of COVID-19, there have been significant informal, patient-led efforts to report and track the 109 various symptoms of long COVID (Patient Led Research Collaborative, 2023). Third, symptoms 110 occurring during the long COVID episode must be separated from the initial episode of COVID itself, 111 which may vary in length and severity. Fourth, like other medical conditions, a claims-based definition 112 must be clinically relevant with respect to disease severity, and account for health conditions a patient 113 may have had prior to their COVID and long COVID episodes. 114 Given these challenges, we tested several approaches to defining long COVID using data from the N3C 115 Enclave. We first defined a six-month lookback & look-forward window around each patients' index 116 COVID-19 episode and limited our sample to patients who have healthcare utilization (defined as having 117 a condition recorded in the N3C database) prior to, and after, these windows. This allowed us to 118 accurately classify a lack of healthcare utilization during the lookback or look-forward windows as true 119 non-utilization, as opposed to a patient death, relocation, or otherwise missing data. We then identified all 120 OMOP concept ID condition codes that appear on a patient's record between 90 and 180 days following 121 their index COVID-19 diagnosis. Excluding conditions recorded within 90 days after an initial COVID-122 19 diagnosis ensured that we do not flag symptoms of COVID-19 as symptoms of long COVID. From the 123 resulting set of symptoms, we removed any symptoms that appeared on a patient's record during their 124 lookback window. A drawback of this approach is that it reduces the likelihood that we detect long 125 COVID cases among people with chronic conditions or comorbidities, who are actually most likely to 126 contract long COVID. We additionally removed any symptoms during the look-forward period that do 127 not appear on the list of 76 conditions in the N3C Long COVID OMOP condition code set. The 128 remaining symptoms were considered as the patient's long COVID symptom burden.

White Paper: Can longitudinal electronic health record data identify patients at higher risk of developing long COVID?

129	We considered that the N3C long COVID OMOP condition code set contains several potential
130	redundancies, and that these conditions might be over-reported in claims and EHR data due to upcoding.
131	For example, the following pairs of symptoms were similar to one another, yet each appeared as an
132	independent item in the OMOP code set: sleep disturbances and insomnia, nausea and vomiting, body
133	aches and muscle pain, and fatigue and exercise intolerance. We consolidated these redundancies in a
134	patient's look-forward period prior to calculating each patient's long COVID symptom score. This
135	reduced the number of long covid symptoms from 76 to 72.
136	3 symptom cluster approach
137	Lastly, we built off of the recent literature by calculating a cluster-specific score for each of three
138	symptom clusters (Cognitive, Respiratory, and Fatigue) (Global Burden of Disease Long COVID
139	Collaborators, 2022). We created three cluster-specific, binary long COVID definitions based on a cutoff
140	of at least 3 distinct long COVID symptoms within the relevant cluster. This approach provided a few
141	advantages: it built off the clinical literature identifying these three symptom clusters as distinct, allowing
142	us to classify each patient into each subtype without concern for whether a patient exhibits symptoms
143	from multiple clusters. Second, it allowed us to capture variation in the relationship between patient
144	demographics and various long COVID subtypes. Third, it allowed us to draw distinctions between more
145	and less severe symptom clusters of long COVID, and potentially identify predictive targets that capture
146	high-morbidity or high-cost events.

147 3. Characteristics of Sample

- 148 We used the N3C de-identified "tier 2 access" data set.¹ A limitation of our analysis is that the Patient
- 149 Severity and Scores dataset, condition occurrence, and drug exposure datasets are frequently updated

¹ Tire 2 access is the patient level EHR data where 17 patient identifier variables are removed and longitudinal data is data-shifted to safeguard privacy (Haendel et al., 2021). We selected patients for the analysis from the Patient Severity and Scores dataset (Release-v70-2022-03-19). The dataset contains patient level information from all sites. N3C identifies positive COVID-19 cases through their COVID-19 Phenotype Inclusion Criteria (Pfaff, 2022). Though this did not factor into our analysis, another feature of the N3C data is a 1:2 case to control ratio of patients with identifies lab-confirmed, suspected, and possible cases of COVID-19 to patients who have been screen and tested negative for COVID-19. In addition, we linked patient ids from the Patient Severity and Scores dataset with

White Paper: Can longitudinal electronic health record data identify patients at higher risk of developing long COVID?

150	within the N3C data enclave and new records being added. Our analysis used the Patient Severity and
151	Scores dataset version 70 which was released on March 19, 2022. Thus, all patients in our analysis were
152	diagnosed on or before March 19, 2022. Therefore, our results did not capture recent changes in the
153	COVID-19 pandemic including the rise in the prevalence of the omicron variant, vaccination, and vaccine
154	booster doses.
155	For our analysis, we started with 13,151,716 patients from the Patient Severity and Scores database and
156	filtered down to the patients with lab confirmed positive cases (3,724,542 patients). Finally, we selected
157	the patients who had conditions occurrences within the 6 months preceding and proceeding diagnosis of
158	COVID-19, ² whose COVID-19 visit start date was between September 1, 2020, and September 1, 2021,
159	and who did not die from COVID-19. This provided us with our final analytic sample of 1,234,119
160	patients.
161	We selected covariates based on our literature review of covariates other researchers found were related
162	
	to long COVID symptoms (Tsampasian et al., 2023). We identified the following covariates using the
163	to long COVID symptoms (Tsampasian et al., 2023). We identified the following covariates using the Patient Severity and Scores dataset: age, sex, race, ethnicity, and current or former smoking status. We
163 164	to long COVID symptoms (Tsampasian et al., 2023). We identified the following covariates using the Patient Severity and Scores dataset: age, sex, race, ethnicity, and current or former smoking status. We categorized the patient's age at diagnosis into 9 categories (0-9, 10-19, 20-29, 30-39, 40-49, 50-59, 60-69,
163 164 165	to long COVID symptoms (Tsampasian et al., 2023). We identified the following covariates using the Patient Severity and Scores dataset: age, sex, race, ethnicity, and current or former smoking status. We categorized the patient's age at diagnosis into 9 categories (0-9, 10-19, 20-29, 30-39, 40-49, 50-59, 60-69, 70-79, and 80+ years old) for patients missing age, we imputed age as the median age 41.2 which
163 164 165 166	to long COVID symptoms (Tsampasian et al., 2023). We identified the following covariates using the Patient Severity and Scores dataset: age, sex, race, ethnicity, and current or former smoking status. We categorized the patient's age at diagnosis into 9 categories (0-9, 10-19, 20-29, 30-39, 40-49, 50-59, 60-69, 70-79, and 80+ years old) for patients missing age, we imputed age as the median age 41.2 which translates to the age category 40-49. We categorized sex as male, female, or other. Race was defined as
 163 164 165 166 167 	to long COVID symptoms (Tsampasian et al., 2023). We identified the following covariates using the Patient Severity and Scores dataset: age, sex, race, ethnicity, and current or former smoking status. We categorized the patient's age at diagnosis into 9 categories (0-9, 10-19, 20-29, 30-39, 40-49, 50-59, 60-69, 70-79, and 80+ years old) for patients missing age, we imputed age as the median age 41.2 which translates to the age category 40-49. We categorized sex as male, female, or other. Race was defined as White, Black or African American, Asian, Native Hawaiian or Other Pacific Islander, Other, and
 163 164 165 166 167 168 	to long COVID symptoms (Tsampasian et al., 2023). We identified the following covariates using the Patient Severity and Scores dataset: age, sex, race, ethnicity, and current or former smoking status. We categorized the patient's age at diagnosis into 9 categories (0-9, 10-19, 20-29, 30-39, 40-49, 50-59, 60-69, 70-79, and 80+ years old) for patients missing age, we imputed age as the median age 41.2 which translates to the age category 40-49. We categorized sex as male, female, or other. Race was defined as White, Black or African American, Asian, Native Hawaiian or Other Pacific Islander, Other, and Missing/Unknown. Ethnicity was defined as Hispanic or Latino, Not Hispanic or Latino, and Ethnicity

 2 For selecting the patients how has conditions occurrences within 6 months preceding and proceeding diagnosis, we used the condition occurrence dataset (Release-v70-2022-03-19)

two additional datasets provided in N3C, the condition occurrence dataset (Release-v70-2022-03-19) and the drug exposures dataset (Release-v70-2022-03-19) to provide additional longitudinal information about the patients in the database. These condition occurrence dataset records diagnosis, signs, and symptoms of conditions and drug exposure dataset records introduction of drugs into the body of the patient overtime (Observational Health Data Sciences and Informatics, 2018).

White Paper: Can longitudinal electronic health record data identify patients at higher risk of developing long COVID?

170	In addition, we identified the following covariates using the OMOP code set ids in the condition
171	occurrence and drug exposure datasets for the dates prior to the covid diagnosis: COVID-19 vaccination,
172	pregnancy, hypertension, obesity, immunocompromised, and Charlson Comorbidity Index (CCI) score
173	(Glasheen et al., 2019). For each patient, if the OMOP codes for the comorbidity's hypertension, obesity,
174	immunocompromised, or CCI score appear in the condition occurrence data before the COVID-19
175	diagnosis, then we categorized the patient as having the respective comorbidity. We considered a patient
176	vaccinated if a patient received one or more doses of a Pfizer, Moderna, or Johnson and Johnson vaccine
177	before diagnosis of COVID-19 as recorded in the drug exposure dataset. We considered a patient
178	pregnant if the condition start date was within a year of COVID-19 diagnosis. See Appendix A1 for full
179	list of the OMOP codes we used to create the covariates.
180	Our sample was 56% (n = 692,547) female, 68% (n = 1,031,221) White, 2% (n = 25,083) received at least
181	one dose of a COVID-19 vaccine, 22% ($n = 27,3255$) were 60 years old or older, see Table 1 for
182	additional attributes of the analytic sample.
183	Several limitations exist in our data. First, the observed conditions dataset only recorded diagnoses, signs,
184	or symptoms of a condition either observed by a provider or reported by the patient (Blacketer, 2021).
185	This limitation might have affected the makeup of the sample through: 1) underreporting conditions
186	because patients might have had conditions treated at another facility not sharing data with N3C, 2)
187	excluding the healthiest patients because they did not have any reported conditions in the six months
188	before and after the COVID-19 diagnosis. The vaccination status had a similar limitation where
189	vaccination data was reported by clinics, pharmacies, or patients (Blacketer, 2021). Due to this limitation,
190	our sample may have underestimated the vaccination rates if patients received vaccinations at a facility
191	not sharing data with N3C. The low vaccination rates in our data might have led to a weaker relationship
192	between vaccination and long COVID symptoms in our findings. Due to our concerns with the

193 vaccination variable, we choose not to include vaccination in our modeling.

DRAFT 05/31/24 Mathematica® Inc.

White Paper: Can longitudinal electronic health record data identify patients at higher risk of developing long COVID?

194 4. Summary statistics for Cognitive, Fatigue, and Respiratory variations of Long COVID

195	We examined long COVID by three symptom clusters cognitive, fatigue, and respiratory as defined
196	by the Global Burden of Disease Long COVID Collaborators (Global Burden of Disease Long COVID
197	Collaborators, 2022). We classified patients as being positive for the individual symptom clusters if the
198	patients had a qualifying symptom present between 3 to 6 months after having a lab confirmed case of
199	COVID-19 and that symptom was not reported in the 6 months preceding their lab confirmed case of
200	COVID-19. For a full list of the symptoms and OMOP codes we used as qualifying cognitive, fatigue,
201	and respiratory long COVID symptoms, see Appendix A2, A3, and A4 respectively. Then we focused our
202	analysis on the three separate symptom clusters and predicted the risk of a patient having had each
203	symptom cluster of long COVID systems.
204	The fatigue long COVID symptom cluster was the most common in our sample with 4.7% ($n = 57,483$) of
205	all patients, followed by respiratory cluster with 2.5% (n = 30,668) of our sample, and the cognitive
206	symptom cluster with only 0.2% ($n = 2,937$) of the sample (Table 1). In general, for all three symptom
207	clusters, there was an age gradient where patients in younger age groups have lower rates of symptom
208	clusters than patients in older groups. Female patients had higher rates (5.7%) of the fatigue symptom
209	cluster than male patients (3.3%) and there was no difference in rates between the sexes for the cognitive
210	symptom clusters (female = 0.3% ; male = 0.2%) and respiratory (female = 2.6% ; male = 2.3%). Black
211	and White patients had higher prevalence than other race groups for all three symptom clusters. There
212	was not a meaningful difference in prevalence by ethnicity. Patients who had cognitive, fatigue, and
213	respiratory symptom clusters had higher average CCI scores than those who did not experience said
214	symptom clusters. The highest average CCI scores were patients who had cognitive cluster symptoms
215	(mean = 2.7), compared to fatigue (mean = 1.4) and respiratory (mean = 1.4) symptom clusters. For other
216	variables we did not observe large differences between groups.

White Paper: Can longitudinal electronic health record data identify patients at higher risk of developing long COVID?

5. Predictive model for long COVID outcomes

218 Model training methods

219 We trained two types of machine learning models (a binary logistic regression model and a binary random 220 forest model) on all three long COVID clusters separately: respiratory, fatigue, and cognitive. We used a 221 70-30 train-test split, resulting in 863,883 training observations and 370,236 test observations. To 222 accommodate for long COVID being a rare outcome in all three of our clusters, we trained all models on 223 down sampled data and tested them on the original, unbalanced data. To create the down sampled training 224 data, we took five bootstrapped samples with replacement. Each bootstrapped sample had an equal 225 number of positive and negative cases, which was also equal to the total number of positive cases in the 226 original training data.

227 Model performance

The random forest model outperformed the logistic regression model at predicting the respiratory and cognitive clusters, but the logistic regression model slightly outperformed the random forest model at predicting the fatigue outcome (Table 2). In all six models, the AUC remained fairly consistent between the train and test data, but the model precision (a measure of how often a model's positive predictions are correct) dropped quite dramatically between the train and test data. This could be because long COVID was a rare outcome, or that there is low signal in the data.

234 Covariates

To measure feature importance, we considered coefficient values for the binary logistic regression models and impurity-based variable importance scores for the random forest models (Tables 3 and 4). Among our six models, there were some variations in which covariates were most predictive. The CCI score was the most important feature in all three clusters for the random forest models. However, for the binary logistic regression models, all three clusters had different most important features (Table 3). For the respiratory cluster, the two most important features are belonging to the 0 - 9 age group and being a current or former smoker. For the fatigue cluster, the two most important features are belonging to the 0 - 9 age

White Paper: Can longitudinal electronic health record data identify patients at higher risk of developing long COVID?

group and being male. Finally, for the cognitive cluster, the two most important features are being 80

- 243 years old or older and belonging to the 70 79 age group.
- 244 Comparisons with other long COVID predictive models
- 245 One challenge in comparing models is that there is not a consistent definition of long COVID that is
- universally accepted. The two papers described below offer two alternative definitions of long COVID.
- 247 One study also uses data from N3C to predict outcomes of long COVID. The authors consider visiting a
- long COVID clinic as an indicator that a patient has long COVID (Pfaff, 2022). This is a narrower
- 249 definition of long COVID than our definition in this study. Their XGBoost model results in an AUC of
- 250 0.92 for all patients in their sample, 0.90 for hospitalized patients, and 0.85 for non-hospitalized patients.
- 251 The simplicity of their measure could explain why their results are better than the results from our

252 models. However, there are also drawbacks to defining long COVID as a visit to a long COVID clinic. a

- long COVID clinic is a very specific type of care and someone's long COVID symptoms have to be
- 254 pretty severe to be referred to a long COVID clinic. Thus, the Pfaff definition undercounts the number of
- 255 patients with long COVID especially patients with more mild symptoms of long COVID.
- Another study used age, sex, and the number of symptoms a patient experienced in the first week of
- 257 infection to classify duration of COVID-19 as either short (less than 10 days) or long (28 days or more,
- which is shorter than the WHO recommendation) using k-means clustering (Sudre et al., 2021). The
- authors analyzed self-reported data from 4,182 cases of COVID-19 through the COVID Symptom Study
- app and used a random forest model and a logistic regression model to predict long COVID, as defined by
- 261 having symptoms for 28 days or longer. The random forest model, which included first week symptoms
- and other comorbidities, performed moderately well with an AUC of 0.768. The logistic regression model
- was much simpler and included only age, sex, and number of symptoms in the first week, with an AUC of
- 264 0.767. One key difference between Sudre et al and our model is that Sudre et al included the number of
- symptoms in the first week which is likely a proxy for identify which patients had more severe initial
- 266 COVID infections, whereas our model had limited variables representing the severity of initial infection.

White Paper: Can longitudinal electronic health record data identify patients at higher risk of developing long COVID?

267 6. Apply the fair machine learning framework to the long COVID predictive models

268	Timely risk assessment of long COVID outcomes can improve patient care and healthcare resource
269	allocation. However, disparities across different sex, race/ethnicity, and social economic status in
270	COVID-19 patient outcomes have been well-documented(Kharroubi & Diab-El-Harake, 2022; Webb
271	Hooper et al., 2020). For example, while males have high risks for severe COVID outcomes such as death
272	and ICU admission, females have been reported in the literature to have higher risks for long COVID
273	(Cohen & van der Meulen Rodgers, 2023). In addition, compared to white patients, patients from
274	racial/ethnic minority groups had significantly different odds of developing long COVID symptoms and
275	conditions (Khullar et al., 2023). It is important to carefully examine model fairness across different
276	population subgroups to achieve optimal and fair clinical decision-making.
277	We plan to confirm our models achieve similar performances across different sex/race/ethnicity groups by
278	calculating the performance score using AUROC, F1 score, precision, recall, sensitivity, and specificity
279	for males/females, different race groups including White, Black or African American, Asian, Native
280	Hawaiian or Pacific Islander, and Other or Missing/Unknown, and different ethnicity (Hispanic and non-
281	Hispanic) groups. This will allow us to detect if there is any bias in model performance. In addition to
282	model performance, other fairness metrics will also be evaluated since the outcome (diagnoses codes in
283	EHR) is not considered "ground truth". We will also evaluate predictive equality, equal opportunity, and
284	statistical parity of the model predictions.
285	If we detect disparity in fairness metrics, we plan to address it using various techniques including

disparate impact remover (a preprocessing technique that edits input values to increase fairness between groups), reweighting (producing weights for each subgroup for each outcome class to achieve statistical parity), and resampling (oversampling or under-sampling to achieve statistical parity). We will compare the effects of different mitigation techniques and discuss their impact on the balance between model performance and fairness metrics. The method maximizing model predictive performance may be different from the method achieving the highest fairness metrics. We will discuss the trade-off between

White Paper: Can longitudinal electronic health record data identify patients at higher risk of developing long COVID?

292 model performance and fairness in the context of using real-world EHR data to develop predictive models

for long COVID.

294 Conclusion

295 **Overarching takeaways regarding model performance**

In this study, we explored the feasibility to train a predictive model to provide insights into the risk

297 factors for long COVID. We leveraged a diverse and harmonized electronic health record data source and

applied minimum filters to build a model with high potential to be applied to general population. After

using techniques to handle unbalanced sample, our predictive models achieved moderate performance

accuracy (AUC 0.599 - 0.730 for the random forest models, AUC 0.602 - 0.734 for the logistic

301 regression models). It was interesting to observe that logistic regression models have comparable

302 performance to random forest models, potentially because we included relatively limited number of

303 predictors that are easy to acquire. Other predictive models developed in the past had stronger

304 performances but they either leveraged clinical factors that can be hard to acquire such as blood oxygen,

blood pH (Bennett et al., 2021), or they limited the population to a small and relatively homogenous

306 groups of people, such as users of the COVID Symptom Study app or patients visiting a long COVID

307 clinic (Pfaff, 2022; Sudre et al., 2021).

308 Comparison with 19&Me severe COVID risk model

309 Previously we leveraged the same data source (N3C) and machine learning models to build a predictive

310 model for severe COVID-19 outcomes. Severe COVID-19 outcome is defined as having a score of 6 or

311 above using the Clinical Progression Scale (CPS) established by the World Health Organization for

312 COVID-19 clinical research (Marshall et al., 2020). In a sample of 864,8080 COVID-19 positive

patients, 15,401 (1.75%) has this outcome. Many risk factors are related to elevated COVID-19 risk, and

- 314 others have published machine learning models that achieve high predictive performance (AUROC =
- 315 0.87) using a long list of predictors including demographics (age/sex/race), health conditions
- 316 (comorbidities) and clinical characteristics (blood pH, respiratory rate, oxygen saturation...). We limit

White Paper: Can longitudinal electronic health record data identify patients at higher risk of developing long COVID?

317	the predictors to those easily accessible in the 19andMe app (age/sex/race/comorbidities/smoking
318	status/vaccination status). Since the outcome is highly unbalanced, we used down sampling and up
319	weighting to handle the sample unbalance. We experimented with different modeling techniques such as
320	random forest and logistic regression, with and without the downsampling techniques. The best
321	performing model was the logistic regression with downsampled data (Table 2).
322	Implications for future work: learnings on N3C data
323	The N3C is a nationally representative, harmonized data resource that we can leverage for COVID-19
324	research, among other data sources that our team already have experience with. In addition to the data
325	tables that we explored in the current work, several other data tables such as visitation occurrence can be
326	potentially useful for future similar work. In our current work, we can only create a flag variable for
327	whether or not the patient has certain symptoms, without the ability to rate its severity. Information in the
328	visitation occurrence table can be helpful because it has visit start and end date, which can then be used to
329	characterize the severity of the condition. This can be a future area of modeling enhancement.
330	Machine learning models have utilities in building predictive models for both severe COVID outcomes
331	and long COVID. The severe COVID model had better performance, partially because of a clear
332	definition of severe COVID and relative follow-up period. The model building process could benefit
333	from close collaborations between data scientists, health service researchers and clinicians. The models
334	developed in this study may be valuable to both payers to improve their understanding of the risks of their
335	insured population, and to public health officials to better plan for the resources needed to improve
336	population health in the aftermaths of COVID-19 pandemic.

White Paper: Can longitudinal electronic health record data identify patients at higher risk of developing long COVID?

337 Acknowledgements

- 338 This work is supported by Mathematica.
- 339 N3C Attribution

340 The analyses described in this manuscript were conducted with data or tools accessed through the

341 NCATS N3C Data Enclave https://covid.cd2h.org and N3C Attribution & Publication Policy v 1.2-2020-

342 08-25b supported by NCATS Contract No. 75N95023D00001, Axle Informatics Subcontract: NCATS-

343 P00438-B, and [insert additional funding agencies or sources and reference numbers as declared by the

344 contributors in their form response above]. This research was possible because of the patients whose

345 information is included within the data and the organizations (https://ncats.nih.gov/n3c/resources/data-346 contribution/data-transfer-agreement-signatories) and scientists who have contributed to the on-going

development of this community resource [https://doi.org/10.1093/jamia/ocaa196].

348

349 Disclaimer The N3C Publication committee confirmed that this manuscript msid:1865.948 is in

350 accordance with N3C data use and attribution policies; however, this content is solely the responsibility of

the authors and does not necessarily represent the official views of the National Institutes of Health or the

352 N3C program.

353

354 IRB

355 The N3C data transfer to NCATS is performed under a Johns Hopkins University Reliance Protocol #

356 IRB00249128 or individual site agreements with NIH. The N3C Data Enclave is managed under the

authority of the NIH; information can be found at https://ncats.nih.gov/n3c/resources.

358

- 359 Individual Acknowledgements For Core Contributors
- 360 We gratefully acknowledge the following core contributors to N3C:

361

362 Adam B. Wilcox, Adam M. Lee, Alexis Graves, Alfred (Jerrod) Anzalone, Amin Manna, Amit Saha, 363 Amy Olex, Andrea Zhou, Andrew E. Williams, Andrew Southerland, Andrew T. Girvin, Anita Walden, Anjali A. Sharathkumar, Benjamin Amor, Benjamin Bates, Brian Hendricks, Brijesh Patel, Caleb 364 Alexander, Carolyn Bramante, Cavin Ward-Caviness, Charisse Madlock-Brown, Christine Suver, 365 Christopher Chute, Christopher Dillon, Chunlei Wu, Clare Schmitt, Cliff Takemoto, Dan Housman, 366 Davera Gabriel, David A. Eichmann, Diego Mazzotti, Don Brown, Eilis Boudreau, Elaine Hill, Elizabeth 367 Zampino, Emily Carlson Marti, Emily R. Pfaff, Evan French, Farrukh M Koraishy, Federico Mariona, 368 369 Fred Prior, George Sokos, Greg Martin, Harold Lehmann, Heidi Spratt, Hemalkumar Mehta, Hongfang

370 Liu, Hythem Sidky, J.W. Awori Hayanga, Jami Pincavitch, Jaylyn Clark, Jeremy Richard Harper, Jessica

371 Islam, Jin Ge, Joel Gagnier, Joel H. Saltz, Joel Saltz, Johanna Loomba, John Buse, Jomol Mathew, Joni

272 L. Rutter, Julie A. McMurry, Justin Guinney, Justin Starren, Karen Crowley, Katie Rebecca Bradwell,

- 373 Kellie M. Walters, Ken Wilkins, Kenneth R. Gersing, Kenrick Dwain Cato, Kimberly Murray, Kristin
- 374 Kostka, Lavance Northington, Lee Allan Pyles, Leonie Misquitta, Lesley Cottrell, Lili Portilla, Mariam

White Paper: Can longitudinal electronic health record data identify patients at higher risk of developing long COVID?

- 375 Deacy, Mark M. Bissell, Marshall Clark, Mary Emmett, Mary Morrison Saltz, Matvey B. Palchuk,
- 376 Melissa A. Haendel, Meredith Adams, Meredith Temple-O'Connor, Michael G. Kurilla, Michele Morris,
- 377 Nabeel Qureshi, Nasia Safdar, Nicole Garbarini, Noha Sharafeldin, Ofer Sadan, Patricia A. Francis,
- Penny Wung Burgoon, Peter Robinson, Philip R.O. Payne, Rafael Fuentes, Randeep Jawa, Rebecca
- 379 Erwin-Cohen, Rena Patel, Richard A. Moffitt, Richard L. Zhu, Rishi Kamaleswaran, Robert Hurley,
- 380 Robert T. Miller, Saiju Pyarajan, Sam G. Michael, Samuel Bozzette, Sandeep Mallipattu, Satyanarayana
- 381 Vedula, Scott Chapman, Shawn T. O'Neil, Soko Setoguchi, Stephanie S. Hong, Steve Johnson, Tellen D.
- 382 Bennett, Tiffany Callahan, Umit Topaloglu, Usman Sheikh, Valery Gordon, Vignesh Subbian, Warren A.
- 383 Kibbe, Wenndy Hernandez, Will Beasley, Will Cooper, William Hillegass, Xiaohan Tanner Zhang.
- 384 Details of contributions available at covid.cd2h.org/core-contributors
- 385
- 386 Data Partners with Released Data

387 The following institutions whose data is released or pending:

388

389 Available: Advocate Health Care Network — UL1TR002389: The Institute for Translational Medicine 390 (ITM) • Aurora Health Care Inc — UL1TR002373: Wisconsin Network For Health Research • Boston 391 University Medical Campus — UL1TR001430: Boston University Clinical and Translational Science 392 Institute • Brown University — U54GM115677: Advance Clinical Translational Research (Advance-393 CTR) • Carilion Clinic — UL1TR003015: iTHRIV Integrated Translational health Research Institute of 394 Virginia • Case Western Reserve University — UL1TR002548: The Clinical & Translational Science 395 Collaborative of Cleveland (CTSC) • Charleston Area Medical Center — U54GM104942: West Virginia 396 Clinical and Translational Science Institute (WVCTSI) • Children's Hospital Colorado — 397 UL1TR002535: Colorado Clinical and Translational Sciences Institute • Columbia University Irving 398 Medical Center — UL1TR001873: Irving Institute for Clinical and Translational Research • Dartmouth 399 College — None (Voluntary) Duke University — UL1TR002553: Duke Clinical and Translational 400 Science Institute • George Washington Children's Research Institute — UL1TR001876: Clinical and 401 Translational Science Institute at Children's National (CTSA-CN) • George Washington University — UL1TR001876: Clinical and Translational Science Institute at Children's National (CTSA-CN) • Harvard 402 403 Medical School — UL1TR002541: Harvard Catalyst • Indiana University School of Medicine — 404 UL1TR002529: Indiana Clinical and Translational Science Institute • Johns Hopkins University — UL1TR003098: Johns Hopkins Institute for Clinical and Translational Research • Louisiana Public 405 406 Health Institute — None (Voluntary) • Loyola Medicine — Loyola University Medical Center • Loyola University Medical Center — UL1TR002389: The Institute for Translational Medicine (ITM) • Maine 407 408 Medical Center — U54GM115516: Northern New England Clinical & Translational Research (NNE-409 CTR) Network • Mary Hitchcock Memorial Hospital & Dartmouth Hitchcock Clinic — None (Voluntary) 410 • Massachusetts General Brigham — UL1TR002541: Harvard Catalyst • Mayo Clinic Rochester — 411 UL1TR002377: Mayo Clinic Center for Clinical and Translational Science (CCaTS) • Medical University 412 of South Carolina — UL1TR001450: South Carolina Clinical & Translational Research Institute (SCTR) 413 • MITRE Corporation — None (Voluntary) • Montefiore Medical Center — UL1TR002556: Institute for 414 Clinical and Translational Research at Einstein and Montefiore • Nemours - U54GM104941: Delaware 415 CTR ACCEL Program • NorthShore University HealthSystem — UL1TR002389: The Institute for Translational Medicine (ITM) • Northwestern University at Chicago — UL1TR001422: Northwestern 416 417 University Clinical and Translational Science Institute (NUCATS) • OCHIN — INV-018455: Bill and

White Paper: Can longitudinal electronic health record data identify patients at higher risk of developing long COVID?

Melinda Gates Foundation grant to Sage Bionetworks • Oregon Health & Science University ----418 419 UL1TR002369: Oregon Clinical and Translational Research Institute • Penn State Health Milton S. 420 Hershey Medical Center — UL1TR002014: Penn State Clinical and Translational Science Institute • 421 Rush University Medical Center — UL1TR002389: The Institute for Translational Medicine (ITM) • 422 Rutgers, The State University of New Jersey — UL1TR003017: New Jersey Alliance for Clinical and 423 Translational Science • Stony Brook University - U24TR002306 • The Alliance at the University of 424 Puerto Rico, Medical Sciences Campus — U54GM133807: Hispanic Alliance for Clinical and 425 Translational Research (The Alliance) • The Ohio State University — UL1TR002733: Center for Clinical 426 and Translational Science • The State University of New York at Buffalo — UL1TR001412: Clinical and 427 Translational Science Institute • The University of Chicago — UL1TR002389: The Institute for 428 Translational Medicine (ITM) • The University of Iowa — UL1TR002537: Institute for Clinical and 429 Translational Science • The University of Miami Leonard M. Miller School of Medicine -430 UL1TR002736: University of Miami Clinical and Translational Science Institute • The University of 431 Michigan at Ann Arbor — UL1TR002240: Michigan Institute for Clinical and Health Research • The University of Texas Health Science Center at Houston --- UL1TR003167: Center for Clinical and 432 433 Translational Sciences (CCTS) • The University of Texas Medical Branch at Galveston — 434 UL1TR001439: The Institute for Translational Sciences • The University of Utah — UL1TR002538: 435 Uhealth Center for Clinical and Translational Science • Tufts Medical Center — UL1TR002544: Tufts 436 Clinical and Translational Science Institute • Tulane University — UL1TR003096: Center for Clinical 437 and Translational Science • The Queens Medical Center — None (Voluntary) • University Medical 438 Center New Orleans — U54GM104940: Louisiana Clinical and Translational Science (LA CaTS) Center 439 • University of Alabama at Birmingham — UL1TR003096: Center for Clinical and Translational Science 440 University of Arkansas for Medical Sciences — UL1TR003107: UAMS Translational Research Institute • University of Cincinnati — UL1TR001425: Center for Clinical and Translational Science and 441 Training • University of Colorado Denver, Anschutz Medical Campus - UL1TR002535: Colorado 442 443 Clinical and Translational Sciences Institute • University of Illinois at Chicago - UL1TR002003: UIC Center for Clinical and Translational Science • University of Kansas Medical Center — UL1TR002366: 444 445 Frontiers: University of Kansas Clinical and Translational Science Institute • University of Kentucky — 446 UL1TR001998: UK Center for Clinical and Translational Science • University of Massachusetts Medical 447 School Worcester — UL1TR001453: The UMass Center for Clinical and Translational Science 448 (UMCCTS) • University Medical Center of Southern Nevada - None (voluntary) • University of 449 Minnesota — UL1TR002494: Clinical and Translational Science Institute • University of Mississippi 450 Medical Center — U54GM115428: Mississippi Center for Clinical and Translational Research (CCTR) • 451 University of Nebraska Medical Center — U54GM115458: Great Plains IDeA-Clinical & Translational 452 Research • University of North Carolina at Chapel Hill — UL1TR002489: North Carolina Translational and Clinical Science Institute • University of Oklahoma Health Sciences Center — U54GM104938: 453 454 Oklahoma Clinical and Translational Science Institute (OCTSI) • University of Pittsburgh — 455 UL1TR001857: The Clinical and Translational Science Institute (CTSI) • University of Pennsylvania — 456 UL1TR001878: Institute for Translational Medicine and Therapeutics • University of Rochester — 457 458 UL1TR001855: The Southern California Clinical and Translational Science Institute (SC CTSI) • 459 University of Vermont — U54GM115516: Northern New England Clinical & Translational Research (NNE-CTR) Network • University of Virginia — UL1TR003015: iTHRIV Integrated Translational health 460 Research Institute of Virginia • University of Washington — UL1TR002319: Institute of Translational 461 462 Health Sciences • University of Wisconsin-Madison - UL1TR002373: UW Institute for Clinical and Translational Research • Vanderbilt University Medical Center - UL1TR002243: Vanderbilt Institute 463

White Paper: Can longitudinal electronic health record data identify patients at higher risk of developing long COVID?

for Clinical and Translational Research • Virginia Commonwealth University — UL1TR002649: C. 464 Kenneth and Dianne Wright Center for Clinical and Translational Research • Wake Forest University 465 466 Health Sciences — UL1TR001420: Wake Forest Clinical and Translational Science Institute • 467 Washington University in St. Louis - UL1TR002345: Institute of Clinical and Translational Sciences • Weill Medical College of Cornell University --- UL1TR002384: Weill Cornell Medicine Clinical and 468 469 Translational Science Center • West Virginia University — U54GM104942: West Virginia Clinical and 470 Translational Science Institute (WVCTSI) Usubmitted: Icahn School of Medicine at Mount Sinai — 471 UL1TR001433: ConduITS Institute for Translational Sciences • The University of Texas Health Science 472 Center at Tyler — UL1TR003167: Center for Clinical and Translational Sciences (CCTS) • University of 473 California, Davis — UL1TR001860: UCDavis Health Clinical and Translational Science Center • 474 University of California, Irvine — UL1TR001414: The UC Irvine Institute for Clinical and Translational 475 Science (ICTS) • University of California, Los Angeles — UL1TR001881: UCLA Clinical Translational 476 Science Institute • University of California, San Diego — UL1TR001442: Altman Clinical and 477 Translational Research Institute • University of California, San Francisco — UL1TR001872: UCSF Clinical and Translational Science Institute NYU Langone Health Clinical Science Core, Data Resource 478 479 Core, and PASC Biorepository Core --- OTA-21-015A: Post-Acute Sequelae of SARS-CoV-2 Infection Initiative (RECOVER) Pending: Arkansas Children's Hospital — UL1TR003107: UAMS Translational 480 481 Research Institute • Baylor College of Medicine --- None (Voluntary) • Children's Hospital of 482 Philadelphia — UL1TR001878: Institute for Translational Medicine and Therapeutics • Cincinnati 483 Children's Hospital Medical Center — UL1TR001425: Center for Clinical and Translational Science and 484 Training • Emory University — UL1TR002378: Georgia Clinical and Translational Science Alliance • 485 HonorHealth — None (Voluntary) • Loyola University Chicago — UL1TR002389: The Institute for 486 Translational Medicine (ITM) • Medical College of Wisconsin — UL1TR001436: Clinical and 487 Translational Science Institute of Southeast Wisconsin • MedStar Health Research Institute -- None (Voluntary) • Georgetown University ---- UL1TR001409: The Georgetown-Howard Universities Center 488 489 for Clinical and Translational Science (GHUCCTS) • MetroHealth — None (Voluntary) • Montana State 490 University - U54GM115371: American Indian/Alaska Native CTR • NYU Langone Medical Center -491 UL1TR001445: Langone Health's Clinical and Translational Science Institute • Ochsner Medical Center 492 - U54GM104940: Louisiana Clinical and Translational Science (LA CaTS) Center • Regenstrief 493 Institute — UL1TR002529: Indiana Clinical and Translational Science Institute • Sanford Research — 494 None (Voluntary) • Stanford University ---- UL1TR003142: Spectrum: The Stanford Center for Clinical 495 and Translational Research and Education • The Rockefeller University — UL1TR001866: Center for 496 Clinical and Translational Science • The Scripps Research Institute — UL1TR002550: Scripps Research 497 Translational Institute • University of Florida — UL1TR001427: UF Clinical and Translational Science 498 Institute • University of New Mexico Health Sciences Center — UL1TR001449: University of New 499 Mexico Clinical and Translational Science Center • University of Texas Health Science Center at San 500 Antonio — UL1TR002645: Institute for Integration of Medicine and Science • Yale New Haven Hospital 501 - UL1TR001863: Yale Center for Clinical Investigation

White Paper: Can longitudinal electronic health record data identify patients at higher risk of developing long COVID?

502 References

- 503 Bennett, T. D., Moffitt, R. A., Hajagos, J. G., Amor, B., Anand, A., Bissell, M. M., Bradwell, K. R.,
- 504 Bremer, C., Byrd, J. B., Denham, A., DeWitt, P. E., Gabriel, D., Garibaldi, B. T., Girvin, A. T.,
- 505 Guinney, J., Hill, E. L., Hong, S. S., Jimenez, H., Kavuluru, R., ... National COVID Cohort
- 506 Collaborative (N3C) Consortium. (2021). Clinical Characterization and Prediction of Clinical
- 507 Severity of SARS-CoV-2 Infection Among US Adults Using Data From the US National COVID
- 508 Cohort Collaborative. JAMA Network Open, 4(7), e2116901.
- 509 https://doi.org/10.1001/jamanetworkopen.2021.16901
- 510 Blacketer, C. (2021, January 11). Chapter 4 The Common Data Model. The Book of OHDSI.
- 511 https://ohdsi.github.io/TheBookOfOhdsi/
- 512 CDC. (2022, June 22). Nearly One in Five American Adults Who Have Had COVID-19 Still Have "Long
- 513 *COVID.*" https://www.cdc.gov/nchs/pressroom/nchs_press_releases/2022/20220622.htm
- 514 CDC. (2023, January 4). Long COVID Household Pulse Survey—COVID-19.
- 515 https://www.cdc.gov/nchs/covid19/pulse/long-covid.htm
- 516 Cohen, J., & van der Meulen Rodgers, Y. (2023). An intersectional analysis of long COVID prevalence.
- 517 International Journal for Equity in Health, 22, 261. https://doi.org/10.1186/s12939-023-02072-5
- 518 Crook, H., Raza, S., Nowell, J., Young, M., & Edison, P. (2021). Long covid—Mechanisms, risk factors,

519 and management. *BMJ*, 374, n1648. https://doi.org/10.1136/bmj.n1648

- 520 Cutler, D. (2022, July 22). *The Economic Cost of Long COVID: An Update*.
- 521 https://scholar.harvard.edu/files/cutler/files/long_covid_update_7-22.pdf
- 522 Cutler, D. M., & Summers, L. H. (2020). The COVID-19 Pandemic and the \$16 Trillion Virus. JAMA,
- 523 324(15), 1495–1496. https://doi.org/10.1001/jama.2020.19759
- 524 Glasheen, W. P., Cordier, T., Gumpina, R., Haugh, G., Davis, J., & Renda, A. (2019). Charlson
- 525 Comorbidity Index: ICD-9 Update and ICD-10 Translation. American Health & Drug Benefits,
- 526 *12*(4), Article 4.

White Paper: Can longitudinal electronic health record data identify patients at higher risk of developing long COVID?

527	Global Burden of Disease Long COVID Collaborators. (2022). Estimated Global Proportions of
528	Individuals With Persistent Fatigue, Cognitive, and Respiratory Symptom Clusters Following
529	Symptomatic COVID-19 in 2020 and 2021. JAMA, 328(16), 1604–1615.
530	https://doi.org/10.1001/jama.2022.18931
531	Haendel, M. A., Chute, C. G., Bennett, T. D., Eichmann, D. A., Guinney, J., Kibbe, W. A., Payne, P. R.
532	O., Pfaff, E. R., Robinson, P. N., Saltz, J. H., Spratt, H., Suver, C., Wilbanks, J., Wilcox, A. B.,
533	Williams, A. E., Wu, C., Blacketer, C., Bradford, R. L., Cimino, J. J., N3C Consortium.
534	(2021). The National COVID Cohort Collaborative (N3C): Rationale, design, infrastructure, and
535	deployment. Journal of the American Medical Informatics Association: JAMIA, 28(3), 427-443.
536	https://doi.org/10.1093/jamia/ocaa196
537	Herman, E., Shih, E., & Cheng, A. (2022). Long COVID: Rapid Evidence Review. American Family
538	Physician, 106(5), 523–532.
539	Kharroubi, S. A., & Diab-El-Harake, M. (2022). Sex-differences in COVID-19 diagnosis, risk factors and
540	disease comorbidities: A large US-based cohort study. Frontiers in Public Health, 10, 1029190.
541	https://doi.org/10.3389/fpubh.2022.1029190
542	Khullar, D., Zhang, Y., Zang, C., Xu, Z., Wang, F., Weiner, M. G., Carton, T. W., Rothman, R. L., Block,
543	J. P., & Kaushal, R. (2023). Racial/Ethnic Disparities in Post-acute Sequelae of SARS-CoV-2
544	Infection in New York: An EHR-Based Cohort Study from the RECOVER Program. Journal of
545	General Internal Medicine, 38(5), 1127-1136. https://doi.org/10.1007/s11606-022-07997-1
546	Klaassen, F., Chitwood, M. H., Cohen, T., Pitzer, V. E., Russi, M., Swartwood, N. A., Salomon, J. A., &
547	Menzies, N. A. (2022). Changes in population immunity against infection and severe disease
548	from SARS-CoV-2 Omicron variants in the United States between December 2021 and November
549	2022 (p. 2022.11.19.22282525). medRxiv. https://doi.org/10.1101/2022.11.19.22282525
550	Mancini, D. M., Brunjes, D. L., Lala, A., Trivieri, M. G., Contreras, J. P., & Natelson, B. H. (2021). Use
551	of Cardiopulmonary Stress Testing for Patients With Unexplained Dyspnea Post-Coronavirus
552	Disease. JACC: Heart Failure, 9(12), 927-937. https://doi.org/10.1016/j.jchf.2021.10.002

White Paper: Can longitudinal electronic health record data identify patients at higher risk of developing long COVID?

553	Marshall, J. C., Murthy, S., Diaz, J., Adhikari, N. K., Angus, D. C., Arabi, Y. M., Baillie, K., Bauer, M.,
554	Berry, S., Blackwood, B., Bonten, M., Bozza, F., Brunkhorst, F., Cheng, A., Clarke, M., Dat, V.
555	Q., de Jong, M., Denholm, J., Derde, L., Zhang, J. (2020). A minimal common outcome
556	measure set for COVID-19 clinical research. The Lancet Infectious Diseases, 20(8), e192-e197.
557	https://doi.org/10.1016/S1473-3099(20)30483-7
558	Nasserie, T., Hittle, M., & Goodman, S. N. (2021). Assessment of the Frequency and Variety of
559	Persistent Symptoms Among Patients With COVID-19: A Systematic Review. JAMA Network
560	Open, 4(5), e2111417. https://doi.org/10.1001/jamanetworkopen.2021.11417
561	Nittas, V., Gao, M., West, E. A., Ballouz, T., Menges, D., Wulf Hanson, S., & Puhan, M. A. (2022). Long
562	COVID Through a Public Health Lens: An Umbrella Review. Public Health Reviews, 43,
563	1604501. https://doi.org/10.3389/phrs.2022.1604501
564	Observational Health Data Sciences and Informatics. (2018). COVID-19 Clinical Data Warehouse Data
565	Dictionary Based on OMOP Common Data Model Specifications Version 5.3. National Center
566	for Advancing Translational Sciences (NCATS).
567	https://ncats.nih.gov/files/OMOP_CDM_COVID.pdf
568	Patient Led Research Collaborative. (2023). About the Patient-Led Research Collaborative. Patient Led
569	Research Collaborative – for Long COVID. https://patientresearchcovid19.com/
570	Pfaff, E. R. (2022, March 11). Latest Phenotype [GitHub]. National-COVID-Cohort-Collaborative.
571	https://github.com/National-COVID-Cohort-
572	Collaborative/Phenotype_Data_Acquisition/wiki/Latest-Phenotype
573	Sudre, C. H., Murray, B., Varsavsky, T., Graham, M. S., Penfold, R. S., Bowyer, R. C., Pujol, J. C.,
574	Klaser, K., Antonelli, M., Canas, L. S., Molteni, E., Modat, M., Jorge Cardoso, M., May, A.,
575	Ganesh, S., Davies, R., Nguyen, L. H., Drew, D. A., Astley, C. M., Steves, C. J. (2021).
576	Attributes and predictors of long COVID. Nature Medicine, 27(4), Article 4.
577	https://doi.org/10.1038/s41591-021-01292-y

DRAFT 05/31/24 Mathematica® Inc.

White Paper: Can longitudinal electronic health record data identify patients at higher risk of developing long COVID?

570 Isampasian, V., Eignazary, II., Chauopaunyay, K., Douski, Wi., Namg, T. K. T., Oarg, T., Clark,	I., Challopauliyay, K., Deuski, WI., Mailig, T. K. F., Oalg, F., Claik, A.,
---	---

- 579 Ntatsaki, E., & Vassiliou, V. S. (2023). Risk Factors Associated With Post–COVID-19
- 580 Condition: A Systematic Review and Meta-analysis. *JAMA Internal Medicine*.
- 581 https://doi.org/10.1001/jamainternmed.2023.0750
- 582 Webb Hooper, M., Nápoles, A. M., & Pérez-Stable, E. J. (2020). COVID-19 and Racial/Ethnic
- 583 Disparities. JAMA, 323(24), 2466–2467. https://doi.org/10.1001/jama.2020.8598
- 584 World Health Organization. (2021, October 6). A clinical case definition of post COVID-19 condition by
- 585 a Delphi consensus, 6 October 2021. https://www.who.int/publications-detail-redirect/WHO-
- 586 2019-nCoV-Post_COVID-19_condition-Clinical_case_definition-2021.1

587

588 Tables

589 Table 1: Analytic Sample

		Cognitive Symptom Cluster		Fatigue Symptom Cluster		Respiratory Symptom Cluster	
		Positive N (%)	Negative N (%)	Positive N (%)	Negative N (%)	Positive N (%)	Negative N (%)
Total		2,937 (0.2%)	1,231,182 (99.8%)	57,483 (4.7%)	1,176,636 (95.3%)	30,668 (2.5%)	1,203,451 (97.5%)
Age		60.1 (SD: 17.22)	41.4 (SD: 20.72)	44.1 (SD: 19.2)	41.3 (SD: 20.8)	47.0 (SD: 22)	41.3 (SD: 20.68)
Age gro	oup:						
	0-9	< 20 ‡	79,370 ¶	1,217 (1.5%)	78,161 (98.5%)	2,383 (3%)	76,995 (97%)
	10-19	< 45 ‡	125,311 ¶	4,841 (3.9%)	120,516 (96.1%)	1,754 (1.4%)	123,603 (98.6%)
	20-29	115 (0.1%)	184,951 (99.9%)	8,904 (4.8%)	176,162 (95.2%)	2,873 (1.6%)	182,193 (98.4%)
	30-39	179 (0.1%)	188,841 (99.9%)	9,583 (5.1%)	179,437 (94.9%)	3,409 (1.8%)	185,611 (98.2%)
	40-49	451 (0.2%)	194,235 (99.8%)	10,029 (5.2%)	184,657 (94.8%)	4,561 (2.3%)	190,125 (97.7%)
	50-59	474 (0.3%)	186,883 (99.7%)	9,173 (4.9%)	178,184 (95.1%)	5,407 (2.9%)	181,950 (97.1%)
	60-69	623 (0.4%)	150,740 (99.6%)	7,393 (4.9%)	143,970 (95.1%)	5,297 (3.5%)	146,066 (96.5%)
	70-79	681 (0.8%)	87,738 (99.2%)	4,597 (5.2%)	83,822 (94.8%)	3,665 (4.1%)	84,754 (95.9%)
	80+	363 (1.1%)	33,110 (98.9%)	1,746 (5.2%)	31,727 (94.8%)	1,319 (3.9%)	32,154 (96.1%)
Sex:							
	Female	1,751 (0.3%)	690,796 (99.7%)	39,362 (5.7%)	653,185 (94.3%)	18,164 (2.6%)	674,383 (97.4%)
	Male	1,186 (0.2%)	540,035 (99.8%)	18,111‡ (3.3%)	523,112 (96.7%)	12,501‡ (2.3%)	528,718 (97.7%)
	Other	0 (0%)	351 (100%)	< 20 ‡	337 ¶	< 20 ‡	352 ¶
Race:							
	White	2,163 (0.3%)	845,108 (99.7%)	41,449 (4.9%)	805,822 (95.1%)	21,293 (2.5%)	825,978 (97.5%)
	Black or African American	412 (0.2%)	172,825 (99.8%)	8,068 (4.7%)	165,169 (95.3%)	5,186 (3%)	168,051 (97%)
	Asian	56 (0.2%)	25,719 (99.8%)	929 (3.6%)	24,846 (96.4%)	619 (2.4%)	25,156 (97.6%)
	Native Hawaiian or Pacific Islander	< 20 ‡	1,866 ¶	61 (3.3%)	1,805 (96.7%)	38 (2%)	1,828 (98%)
	Other	< 20 ‡	10,393 ¶	470 (4.5%)	9,937 (95.5%)	286 (2.7%)	10,121 (97.3%)
	Missing/Unknown	289 (0.2%)	175,274 (99.8%)	6,506 (3.7%)	169,057 (96.3%)	3,246 (1.8%)	172,317 (98.2%)

Ethnicity:						
Hispanic or Latino	295 (0.2%)	167,080 (99.8%)	7,691 (4.6%)	159,684 (95.4%)	3,664 (2.2%)	163,711 (97.8%)
Not Hispanic or Latino	2,408 (0.3%)	946,774 (99.7%)	45,876 (4.8%)	903,306 (95.2%)	24,966 (2.6%)	924,216 (97.4%)
Ethnicity Missing or Unknown	234 (0.2%)	117,328 (99.8%)	3,916 (3.3%)	113,646 (96.7%)	2,038 (1.7%)	115,524 (98.3%)
COVID-19 vaccination:						
Yes	84 (0.3%)	24,999 (99.7%)	1,034 (4.1%)	24,049 (95.9%)	569 (2.3%)	24,514 (97.7%)
No	2,853 (0.2%)	1,206,183 (99.8%)	56,449 (4.7%)	1,152,587 (95.3%)	30,099 (2.5%)	1,178,937 (97.5%)
Smoking status:						
Current or former smoker	529 (0.4%)	146,835 (99.6%)	9,472 (6.4%)	137,892 (93.6%)	5,486 (3.7%)	141,878 (96.3%)
Non-smoker	2,408 (0.2%)	1,084,347 (99.8%)	48,011 (4.4%)	1,038,744 (95.6%)	25,182 (2.3%)	1,061,573 (97.7%)
Hypertension	29 (0.7%)	4,101 (99.3%)	329 (8.0%)	3,801 (92.0%)	172 (4.2%)	3,958 (95.8%)
Obesity	590 (0.5%)	115,173 (99.5%)	9,581 (8.3%)	106,182 (91.7%)	5,281 (4.6%)	110,482 (95.4%)
Immunocompromised	< 20 ‡	138 ¶	< 20 ‡	129 ¶	< 20 ‡	128 ¶
Pregnant	< 20 ‡	2,488 ¶	216 (8.7%)	2,276 (91.3%)	56 (2.2%)	2,436 (97.8%)
CCI Score	2.7 (SD: 3.11)	0.8 (SD: 1.73)	1.4 (SD: 2.35)	0.7 (SD: 1.7)	1.6 (SD: 2.51)	0.7 (SD: 1.71)

590 ‡ To comply with N3C policy, counts below 20 are displayed as < 20, and in this case, additional values must be skewed by up to 5 to render it

591 impossible to back-calculate precise counts fewer than 20 for the following categories: Age Group 0-9, Sex Other, Native Hawaiian or Pacific

592 Islander, Race Other, and Pregnant.

593 ¶ This proportion is one of the two columns that sum up to one. Reporting it would enable the calculation of a cell size < 20. Therefore we mark it 594 as too small to quantitatively report.

595 Abbreviations: SD: standard deviation; CCI: Charlson Comorbidity Index

White Paper: Can longitudinal electronic health record data identify patients at higher risk of developing long COVID?

596 Table 2: Model Performance Results

Long COVID Outcome	Model Type	Performance Metric	Train Sample	Test Sample
Respiratory	Logistic	AUC	0.616	0.617
		F1	0.596	0.077
		Accuracy	0.616	0.660
		Precision	0.628	0.041
		Sensitivity	0.568	0.572
		Specificity	0.664	0.662
	Random Forest	AUC	0.625	0.624
		F1	0.601	0.081
		Accuracy	0.625	0.679
		Precision	0.642	0.043
		Sensitivity	0.565	0.566
		Specificity	0.685	0.682
Fatigue	Logistic	AUC	0.604	0.602
		F1	0.607	0.123
		Accuracy	0.604	0.594
		Precision	0.602	0.068
		Sensitivity	0.613	0.611
		Specificity	0.594	0.593
	Random Forest	AUC	0.603	0.599
		F1	0.578	0.127
		Accuracy	0.603	0.656
		Precision	0.617	0.072
		Sensitivity	0.545	0.537
		Specificity	0.662	0.661
Cognitive	Logistic	AUC	0.723	0.734
		F1	0.717	0.013
		Accuracy	0.723	0.743
		Precision	0.734	0.007
		Sensitivity	0.702	0.725
		Specificity	0.745	0.743
	Random Forest	AUC	0.732	0.730
		F1	0.732	0.013
		Accuracy	0.732	0.723
		Precision	0.732	0.006
		Sensitivity	0.732	0.737
		Specificity	0.731	0.723

597 Abbreviations: AUC: Area under the curve

White Paper: Can longitudinal electronic health record data identify patients at higher risk of developing long COVID?

598 Table 3: Coefficient Values for the Binary Logistic Regression Models

Coeffi	icient	Cognitive	Fatigue	Respiratory
Age	0-9	-1.367	-1.070	0.651
	10-19	-0.988	-0.178	-0.167
	20-29	-0.331	0.002	-0.085
	30-39	Reference	Reference	Reference
	40-49	0.663	-0.057	0.166
	50-59	0.781	-0.110	0.351
	60-69	0.945	-0.241	0.472
	70-79	1.598	-0.288	0.522
	80+	1.892	-0.287	0.504
Sex	Female	Reference	Reference	Reference
	Male	-0.211	-0.539	-0.176
	Other	-0.117	-0.147	-0.196
Race	White	Reference	Reference	Reference
	Black or African American	-0.054	-0.178	0.084
	Asian	-0.064	-0.274	0.019
	Native Hawaiian or Pacific Islander	-0.430	-0.462	-0.248
	Other	-0.454	0.111	0.052
	Missing/Unknown	-0.254	-0.263	-0.277
Ethnicity	Not Hispanic or Latino	Reference	Reference	Reference
	Hispanic or Latino	0.084	0.063	0.016
	Ethnicity Missing or Unknown	-0.006	-0.215	-0.234
COVID-19 vaccination	No	Reference	Reference	Reference
	Yes	-0.397	-0.406	-0.338
Smoking status:	Non-smoker	Reference	Reference	Reference
	Current or Former smoker	0.345	0.316	0.386
Hypertension	No	Reference	Reference	Reference
	Yes	0.298	0.130	-0.012
Obesity	No	Reference	Reference	Reference
	Yes	0.431	0.429	0.413
Immunocompromised	No	Reference	Reference	Reference
	Yes	0.214	-0.056	0.092
Pregnant	No	Reference	Reference	Reference
	Yes	0.293	0.286	-0.076
CCI Score		0.237	0.160	0.166

599 Abbreviations: CCI: Charlson Comorbidity Index

White Paper: Can longitudinal electronic health record data identify patients at higher risk of developing long COVID?

600 Table 4: Impurity-Based Variable Importance Scores for the Random Forest Models

Variable Importance Score		Cognitive	Fatigue	Respiratory
Age	0-9	0.057	0.124	0.014
	10-19	0.092	0.008	0.061
	20-29	0.064	0.006	0.060
	30-39	Reference	Reference	Reference
	40-49	0.003	0.003	0.003
	50-59	0.007	0.002	0.005
	60-69	0.019	0.002	0.033
	70-79	0.124	0.003	0.044
	80+	0.078	0.002	0.012
Sex	Female	Reference	Reference	Reference
	Male	0.007	0.214	0.008
	Other	0.000	0.000	0.000
Race	White	Reference	Reference	Reference
	Black or African American	0.004	0.003	0.007
	Asian	0.003	0.003	0.001
	Native Hawaiian or Pacific Islander	0.000	0.001	0.001
	Other	0.002	0.001	0.001
	Missing/Unknown	0.010	0.023	0.031
Ethnicity	Not Hispanic or Latino	Reference	Reference	Reference
	Hispanic or Latino	0.006	0.004	0.004
	Ethnicity Missing or Unknown	0.005	0.027	0.019
COVID-19 vaccination	No	Reference	Reference	Reference
	Yes	0.003	0.003	0.003
Smoking status:	Non-smoker	Reference	Reference	Reference
	Current or Former smoker	0.018	0.048	0.061
Hypertension	No	Reference	Reference	Reference
	Yes	0.003	0.002	0.002
Obesity	No	Reference	Reference	Reference
	Yes	0.045	0.128	0.122
Immunocompromised	No	Reference	Reference	Reference
	Yes	0.000	0.000	0.000
Pregnant	No	Reference	Reference	Reference
	Yes	0.001	0.001	0.001
CCI Score		0.445	0.394	0.507

601 Abbreviations: CCI: Charlson Comorbidity Index